Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure

Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery.

Reemplazo Mitral Transcatéter en Fallas de Bioprótesis

Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the aforementioned cases of bioprosthesis failure. However, unfortunately, we currently lack comprehensive analyses and large-scale randomized studies.

In this study, researchers conducted an analysis of 20 consecutive symptomatic patients who underwent TMViV replacement due to bioprosthesis failure.

Subjects with mitral annulus, annular calcification in the surgical bioprosthesis, or a transapical percutaneous valve were excluded.

The average age was 64 years, and 12 patients were women. More than half of the patients had diabetes, preserved renal function, an STS Score of 8.1%, and a EuroSCORE II of 9.2%.

Read also: Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2.

Before the procedure, ejection fraction was 44%, with a mean gradient of 13 mmHg. Bioprosthesis failure presented as stenosis with regurgitation in 12 patients, stenosis alone in 5 cases, and regurgitation alone in 2.

The procedure was successful in all patients, with no mortality, infarcton, or stroke. Three patients experienced major bleeding, one required automatic implantable cardioverter defibrillator (AICD), another needed dialysis, and the average hospital stay was 7 days.

Mortality at 30 days and one year was 1 patient and 2 patients, respectively.

Read also: Use of Apixaban and Post TAVR Valve Thrombosis.

After one year of follow-up, all patients were in functional classes I-II, with a gradient of 6 mmHg and an ejection fraction of 44%. All continued anticoagulation.

Conclusion

TMViM replacement with Meril Myval can be performed safely, with high technical success and low mortality at 30 days and one year.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical Outcomes Following Transcatheter Mitral Valve-in-Valve Replacement Using a Meril Myval Transcatheter Heart Valve.

Reference: Mullasari Ajit Sankardas, et al. Heart, Lung and Circulation (2023) , article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...